View clinical trials related to Smoking Cessation.
Filter by:The current proposal aims to develop and establish the effectiveness of a novel behavioral smoking cessation intervention. Previous research has shown that having smokers engage in episodic future thinking (EFT) about specific positive life outcomes that they could experience if they quit smoking immediately can be an effective means of reducing cigarette consumption. This intervention allowed participants to generate their own general positive life outcomes. While the existing intervention approaches motivation from a generalist perspective, the current proposal seeks to modify this intervention to fit within a Fundamental Social Motives (FSM) framework. The FSM framework posits that there exist individual differences in fundamental social motives such as self-protection, disease avoidance, affiliation, kin care, and mating motives such that some individuals are more motivated to work toward some of these goals than others. Specifically, the current proposal seeks to develop an EFT intervention that appeals to fundamental mating motives by asking participants to imagine positive mating outcomes that they might experience in one year's time if they were to quit smoking immediately. This will be accomplished via two empirical studies. Study 1 will compare the effectiveness of the mating-EFT intervention to the general-EFT intervention and a yoked control condition while examining the possibility that individual differences in relationship status, mating motives, self-efficacy, and nicotine dependence moderate these effects. Study 2 will employ a quasi-experimental design to test the effectiveness of this intervention using a tailored messaging approach, assigning smokers who are either single and motivated to seek new mates or involved in a committed relationship and not motivated to seek new mates to complete the general or mating-EFT or a control task. The investigators predict that the mating-EFT will be more effective than the general EFT in reducing cigarette consumption, particularly if it is administered to participants who have more active mating goals.
Rationale: No studies have examined the effect of varenicline for "gradual" smoking cessation in COPD smokers currently not interested in quitting. Objective: To compare the efficiency of varenicline-assisted "gradual" vs. "abrupt" smoking cessation in low-motivated COPD smokers Setting: Pulmonary outpatient clinic Design: Open, randomized pilot smoking cessation trial Participants: COPD smokers with low motivation to quit. Such low motivation will be defined as a score of ≤ 3 points observed in a 10 cm visual analog scale (0=non motivated; 10=highly motivated). Interventions/procedures: Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months. Measurements: The main outcome measure is carbon monoxide-verified complete abstinence rate (CAR) 6 months after quit-day. Other measures are: CAR at 3 months; point prevalence at 3 and 6 months; change in motivation; cigarettes/day; differential dropout rate; decline in pulmonary function; COPD symptoms, episodes of exacerbation and medication; and adverse events. Sample size: One hundred twenty-one subjects per group will be necessary to detect CAR differences between the two groups of 15% at 6 months. Potential study limitations: The main potential limitation is the lack of 1-yr follow-up. Relevance: This study may provide useful preliminary information on the safety and efficiency of varenicline for "gradual" smoking cessation in low-motivated COPD smokers and it may assist in the preparation of a larger, more comprehensive trial.
The purpose of this study is to determine whether or not motivational interviewing is effective in smoking cessation at general practice setting in China.
A two-arm randomized controlled trial for smokers who are not intent to quit smoking will be proposed in outpatient department clinics of People's Liberation Army General Hospital in Beijing, China. Smoking reduction intervention arm (SRI) consisting of a very brief face-to-face individual smoking reduction intervention lasted about one minute, and five follow-up interventions lasted for about minute each. Control arm (EDA) consisting of a very brief face-to-face individual exercise and dietetic advices lasted for the same intervention time as SRI, and also five follow-up interventions lasted for one minute each with different intervention contents.
AIM: To assess the efficacy of an intervention based on the specific design and implementation of a mobile application (APP) in order to reduce the prevalence of smoking consumption among young people motivated 18 to 30 years METHODS: Cluster randomised clinical trial. Unit of randomization: Primary Health Care Centers (PHCC). Intention to treat analysis. STUDY POPULATION: Motivated young smokers of 10 or more cigarettes per day aged 18 to 30 years consulting for any reason to PHCC and who provided written informed consent to participate in the trial. INTERVENTION: 6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation which includes mobile APPs application. Control group: usual care. OUTCOME MEASURES: Abstinence at 12 months confirmed by exhaled air carbon monoxide concentration of less or iqual 10 parts per million in each control. RESULTS: The application of a smoking cessation intervention with a mobile APPs application will improve the smoking cessation success rate in smokers, besides of their intention or not to give up smoking at baseline.
Bupropion has been used successfully and safely for smoking cessation in adults. It was also used in very few studies among adolescent population. Our hypothesis is that Bupropion would be effective and safe among the adoelscent psychiatric population. A double-blind randomized controlled-trial will be held to determine that.